Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 12.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 225,374 shares of the company’s stock after buying an additional 24,800 shares during the quarter. Hillsdale Investment Management Inc. owned 0.30% of Kiniksa Pharmaceuticals International worth $8,751,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth about $31,000. USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $32,000. Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $43,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 582.4% during the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after purchasing an additional 1,159 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling

In other news, Director Barry D. Quart sold 20,129 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at approximately $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 123,823 shares of company stock worth $5,244,967 in the last three months. 53.48% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on KNSA shares. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a report on Thursday. They issued a “buy” rating and a $62.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.71.

Kiniksa Pharmaceuticals International Trading Up 1.3%

NASDAQ:KNSA opened at $47.77 on Friday. The stock has a 50 day moving average of $42.72 and a 200-day moving average of $39.37. The firm has a market capitalization of $3.62 billion, a PE ratio of 106.16 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $47.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.